Normative database for OCT device cleared by FDA

Article

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

This new tool has been designed to enable the assessment of glaucoma risk from a patient’s first office visit. Additionally, in combination with proprietary fovea-to-disc alignment software and new posterior pole asymmetry analysis the database aims to increase the power of the OCT instrument for glaucoma risk assessment and progression management.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.